PD-1 Antikörper (APC-Cy7)
Kurzübersicht für PD-1 Antikörper (APC-Cy7) (ABIN2660570)
Target
Alle PD-1 (PDCD1) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Aufreinigung
- The antibody was purified by affinity chromatography and conjugated with APC/Cy7 under optimal conditions. The solution is free of unconjugated APC/Cy7 and unconjugated antibody.
-
Isotyp
- IgG2a kappa
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 0.2 mg/mL
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Protect from prolonged exposure to light. Do not freeze.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))
-
Andere Bezeichnung
- CD279
-
Hintergrund
- CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.
-
Pathways
- Cancer Immune Checkpoints
Target
-